An interventional study of DCB catheter in Stenosis of Native Hemodialysis Arteriovenous Fistulas, sponsored by Acotec Scientific Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-01-16.
Sponsored by Acotec Scientific Co., Ltd · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Arteriovenous Fistula with a site in China — 6 open to participants now, 7 under way, none of them phase 3. Arteriovenous Fistula · China.
Among the 20 studies in Arteriovenous Fistula with a site in China, this one is the 9th largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2023, is one of 13 with no phase, and was the 14th registered.
248 studies on the registry are indexed under Arteriovenous Fistula; 44 are open to participants now.
Browse Arteriovenous Fistula studies →6 of the 20 studies in Arteriovenous Fistula with a site in China are open now. Recruiting first, the newest first:
Suzhou Municipal Hospital of Anhui Province · Sites in China
Ages 18–100
DK Medical Technology (Suzhou) Co., Ltd. · Sites in China
Ages 18–80
RenJi Hospital · Sites in China
Ages 18–75
MicroPort NeuroTech Co., Ltd. · Sites in China
Ages 18–80
Ai Peng · Sites in China
Ages 18–75 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 27 Arteriovenous Fistula studies recruiting now, 13 (48%) set no upper age limit and 4 (15%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2023.
This study's planned enrollment of 164 is above the median of 64 across 166 interventional studies indexed under Arteriovenous Fistula.
Median enrollment 184 across the 14 interventional studies, 190 across the 6 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 20 have an industry lead sponsor. The 10 most frequent:
Acotec Scientific Co., Ltd is the lead sponsor of 17 studies on the registry; 8 are open to participants now.
Acotec Scientific Co., Ltd has 2 studies filed under Arteriovenous Fistula — fewer than ten, so there is no comparison to draw.
2 of the studies in Arteriovenous Fistula with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07372027Suzhou Municipal Hospital of Anhui ProvinceSingle-Needle Distal Return for Long-Term Arteriovenous Fistula Care | 2026-12-20 |
| NCT06422845DK Medical Technology (Suzhou) Co., Ltd.Peripheral Scoring Drug-coated Balloon in the Treatment of Hemodialysis Arteriovenous Fistula Stenosis | 2027-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 20 studies in Arteriovenous Fistula with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this prospective,multi-center,single arm study is to obtain further data on the safety and performance of the Acotec Orchid&Dhalia Drug-coated Balloon catheters for the treatment of for the obstructive lesions in the native Arteriovenous Dialysis Fistulae (AVF).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient has a de novo and/or non-stented restenotic lesion(≥50% stenosis)and at least one of the following occurs:
Patient underwent successful crossing of the target lesion with the guide wire and pre-dilatation with a PTA balloon defined as:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Using DCB catheter for the treatment of subjects with a de novo or non-stented restenotic obstructive lesion located in the native arteriovenous dialysis fistulae.
Device: DCB catheter
Trade name of DCB catheter:Acoart Orchid&Dhalia
Target Lesion Primary Patency Rate
Defined as freedom from clinically-driven target lesion revascularization (CD-TLR) or access circuit thrombosis measured.
Time frame: 6 months
Serious Adverse Event Rate
Defined as the Serious Adverse Event (SAE) rate involving the AV access circuit.
Time frame: 30 days
Target Lesion Primary Patency Rate
Defined as freedom from CD-TLR or access thrombosis occurring in the target lesion post-procedure.
Time frame: 12 months,24 months
All-cause mortality Rate
All-cause mortality post procedure
Time frame: 24 months
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2023 (actual). Primary completion is estimated for Dec 2025, 34 months after the start.
Of 84 interventional studies with no phase under Arteriovenous Fistula, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 43. This study's planned 34 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Acotec Scientific Co., Ltd